9 completed, 6 terminated, 3 active not recruiting, 1 recruiting. 11 Phase 2, 9 Phase 1, 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 4, Active not recruiting 3, Terminated 2, Recruiting 1, Suspended 1 |
| Phase 1 | 9 | Completed 5, Terminated 3, Withdrawn 1 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow T-VEC: new trials by email Literature Review of T-VEC trials Research Report on T-VEC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable Disease T-VEC - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Completed | The Netherlands Cancer Institute | 24 | 2020-09-08 | 2025-03-12 |
| Neoadjuvant T-VEC in High Risk Early Melanoma T-Vec - Melanoma | Phase 2 | Suspended | University of California, Davis | 6 | 2020-05-21 | 2023-09-15 |
| T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer Anastrozole, Exemestane, Fulvestrant - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 | Completed | University of California, San Francisco | 20 | 2020-02-05 | 2025-05-21 |
| Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin Panitumumab, Talimogene Laherparepvec - Locally Advanced Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma | Phase 1 | Terminated | Rutgers, The State University of New Jersey | 5 | 2020-01-31 | 2026-01-23 |
| Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery Biopsy Procedure, Biospecimen Collection, Magnetic Resonance Imaging - Leiomyosarcoma, Liposarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 40 | 2019-12-31 | 2026-09-25 |
| Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma T-VEC - Angiosarcoma of Skin | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 5 | 2019-08-20 | 2022-11-01 |
| Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted Ipilimumab, Nivolumab, Talimogene Laherparepvec - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Phase 1 | Terminated | Jonsson Comprehensive Cancer Center | 6 | 2019-07-10 | 2023-08-15 |
| Neoadjuvant Combination Immunotherapy for Stage III Melanoma Pembrolizumab, Talimogene Laherparepvec - Cutaneous Melanoma | Phase 2 | Recruiting | University of Louisville | 28 | 2019-07-03 | 2024-05-02 |
| Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer Capecitabine, Fluorouracil, Leucovorin - Locally Advanced Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 3 | 2019-05-14 | 2024-05-23 |
| Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer Talimogene laherparepvec, Atezolizumab - Breast Cancer | Early Phase 1 | Completed | SOLTI Breast Cancer Research Group | 28 | 2018-12-10 | 2025-09-09 |
| Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma Pembrolizumab, Talimogene Laherparepvec - Advanced Melanoma, Recurrent Melanoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 43 | 2018-06-05 | 2026-05-20 |
| Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma Laboratory Biomarker Analysis, Talimogene Laherparepvec - Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7, Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7 | Phase 1 | Withdrawn | University of California, San Francisco | 2018-06-01 | 2020-07-28 | |
| Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer Talimogene laherparepvec - Pancreatic Cancer | Phase 1 | Completed | Karie D. Runcie, MD | 10 | 2017-11-16 | 2024-11-22 |
| Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 68 | 2017-09-27 | 2026-08-13 |
| Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma Talimogene laherparepvec - Unresectable Stage IIIB-IV Malignant Melanoma | Phase 1 | Completed | Amgen | 18 | 2017-03-07 | 2023-08-09 |
| Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Talimogene Laherparepvec - Malignant Chest Wall Neoplasm, Recurrent Breast Carcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 11 | 2016-08-01 | 2023-01-25 |
| Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma Talimogene Laherparepvec, Pembrolizumab, Placebo - Melanoma | Phase 3 | Terminated | Amgen | 713 | 2014-12-08 | 2022-11-14 |
| Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma Talimogene laherparepvec, Ipilimumab - Melanoma | Phase 1 / Phase 2 | Completed | Amgen | 217 | 2013-02-07 | 2024-05-14 |
| An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016) Talimogene Laherparepvec - Melanoma | Phase 2 | Completed | BioVex Limited | 3 | 2008-08-01 | 2015-12-17 |
| Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer Talimogene Laherparepvec - Pancreatic Cancer | Phase 1 | Completed | BioVex Limited | 17 | 2006-11-01 | 2016-04-15 |
Showing 20 of 21. Sign in to see all of them.
Melanoma (8) · Breast Neoplasms (3) · Pancreatic Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma, Papillary (1) · Breast Carcinoma In Situ (1) · Carcinoma, Basal Cell (1) · Carcinoma, Basosquamous (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Signet Ring Cell (1) · Eccrine Porocarcinoma (1) · Hemangiosarcoma (1) · Histiocytoma, Malignant Fibrous (1) · Inflammatory Breast Neoplasms (1) · Leiomyosarcoma (1)
National Cancer Institute (NCI) (4) · Amgen (3) · BioVex Limited (3) · University of California, San Francisco (2) · H. Lee Moffitt Cancer Center and Research Institute (1) · Jonsson Comprehensive Cancer Center (1) · Karie D. Runcie, MD (1) · M.D. Anderson Cancer Center (1) · Rutgers, The State University of New Jersey (1) · SOLTI Breast Cancer Research Group (1) · The Netherlands Cancer Institute (1) · University of California, Davis (1) · University of Louisville (1)
United States (17) · Canada (2) · France (2) · Germany (2) · Netherlands (2) · Spain (2) · United Kingdom (2) · Australia (1) · Austria (1) · Belgium (1) · Czechia (1) · Finland (1) · Greece (1) · Hungary (1) · Italy (1)
Adam C Berger, MD, FACS (1) · Aleix Prat (1) · Amy J Chien, MD (1) · Cameron Gaskill, MD (1) · John A Glaspy (1) · John Haanen, Prof. (1) · John Mullinax, MD, (1) · John Nemunaitis, MD (1) · Karie Runcie, MD (1) · Michael C Lowe, MD (1) · Michael Egger, MD (1) · Nageshwara V Dasari (1) · Naoto T Ueno (1)
PMID 29896663, PMID 32633563, PMID 35115306, PMID 35927710, PMID 37621406, PMID 39673447, PMID 41271741, PMID 41698899
UM1CA186709 (2), 2014 (1), 2018 (1), P30CA016672 (1), P30CA072720 (1), U10CA180888 (1), UM1CA186686 (1), UM1CA186688 (1), UM1CA186716 (1)